Bharat Immunologicals Biologicals Corp Ltd -- India Stock
Use fundamental data analysis to double-check all available reported financial drivers of Bharat Immunologicals to find out if markets are presently mispricing the company. We found twenty-two available fundamental indicators for Bharat Immunologicals Biologicals Corp Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Bharat Immunologicals fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Use Bharat Immunologicals to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of Bharat Immunologicals to be traded at 20.47 in 30 days
Bharat Immunologicals Biologicals Corp Ltd is rated below average in operating margin category among related companies. It is rated below average in profit margin category among related companies .
Bharat Immunologicals Systematic Risk
The output start index for this execution was five with a total number of output elements of twelve. The Beta measures systematic risk based on how returns on Bharat Immunologicals correlated with the market. If Beta is less then 0 Bharat Immunologicals generally moves in the opposite direction as compared to the market. If Bharat Immunologicals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bharat Immunologicals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bharat Immunologicals is generally in the same direction as the market. If Beta > 1 Bharat Immunologicals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
Chance of Financial Distress
Bharat Immunologicals Biologicals Corp Ltd has less than 19 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info